"Based on currently available information (primarily from clinical trials), the types of side effects associated with ecnoglutide are expected to be similar to those of existing GLP-1 receptor agonists (such as semaglutide or dulaglutide), primarily including gastrointestinal disorders (diarrhea, nausea, vomiting) and decreased appetite
(More information) Prospective cohort studies indicate that higher vitamin C status, assessed by measuring circulating vitamin C, is associated with lower risks of hypertension, coronary heart disease, and stroke
The compound is referenced across a wide spectrum of preclinical models, with most literature focusing on three thematic areas: The 50mg and 100mg vial formats make GHK-Cu particularly suitable for extended research protocols where higher peptide volumes are required compared with the typical 510mg formats used for other research compounds
Key References Sikiric P, et al